# Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma

> **NCT05075460** · PHASE3 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 107 (estimated)

## Conditions studied

- T-cell Lymphoma

## Interventions

- **DRUG:** Tucidinostat, Azacitidine combined with CHOP

## Key facts

- **NCT ID:** NCT05075460
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-01
- **Primary completion:** 2024-05-30
- **Final completion:** 2024-10-30
- **Target enrollment:** 107 (ESTIMATED)
- **Last updated:** 2024-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05075460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05075460, "Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05075460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*